Immunology
173.7K views | +0 today
Follow
Immunology
Teaching and Learning Immunology. Information you never would have searched for!
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

Immunology and Cell Biology - Controversies concerning thymus-derived T cells: fundamental issues and a new perspective - Nature.com

Immunology and Cell Biology - Controversies concerning thymus-derived T cells: fundamental issues and a new perspective - Nature.com | Immunology | Scoop.it

Immunology and Cell Biology 

 

Abstract

Thymus-derived regulatory T cells (Tregs) are considered to be a distinct T-cell lineage that is genetically programmed and specialised for immunosuppression. This perspective is based on the key evidence that CD25+ Tregs emigrate to neonatal spleen a few days later than other T cells and that thymectomy of 3-day-old mice depletes Tregs only, causing autoimmune diseases. Although widely believed, the evidence has never been reproduced as originally reported, and some studies indicate that Tregs exist in neonates. Thus we examine the consequences of the controversial evidence, revisit the fundamental issues of Tregs and thereby reveal the overlooked relationship of T-cell activation and Foxp3-mediated control of the T-cell system. Here we provide a new model of Tregs and Foxp3, a feedback control perspective, which views Tregs as a component of the system that controls T-cell activation, rather than as a distinct genetically programmed lineage. This perspective provides new insights into the roles of self-reactivity, T cell–antigen-presenting cell interaction and T-cell activation in Foxp3-mediated immune regulation.


Via Krishan Maggon
Gilbert C FAURE's insight:

OPEN PAPER

Krishan Maggon 's curator insight, July 28, 2015 11:31 AM

Immunology and Cell Biology advance online publication 28 July 2015; doi: 10.1038/icb.2015.65

Controversies concerning thymus-derived regulatory T cells: fundamental issues and a new perspective
OPEN

Masahiro Ono1,2 and Reiko J Tanaka3

1Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK2Immunobiology Section, Institute of Child Health, University College London, London, UK3Department of Bioengineering, Imperial College London, London, UK

Correspondence: Dr M Ono, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, Room 605, Sir Alexander Fleming Building, South Kensington Campus, Exhibition Road, London SW7 2AZ, UK. E-mail: m.ono@imperial.ac.uk

Received 29 December 2014; Revised 5 June 2015; Accepted 9 June 2015
Advance online publication 28 July 2015

Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy: Cancer Cell

The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy: Cancer Cell | Immunology | Scoop.it

Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technological advances that made checkpoint blockade and T cell engineering possible. In this review, we intend to show that research, not specifically designed to bring relief or cure to any particular disease, can, when creatively exploited, lead to spectacular results in the management of cancer. The discovery of thymus immune function, T cells, and immune surveillance bore the seeds for today’s targeted immune interventions and chimeric antigen receptors.


Via Krishan Maggon
Gilbert C FAURE's insight:
Perspective

The spectacular successes that have been achieved in the immune management of various clinical conditions and especially cancer were borne out of basic research that was creatively exploited by translational researchers. No one could have predicted that investigating how or why virus-induced lymphocytic leukemia needs to develop in the neonatal mouse thymus would reveal the latter’s immunological function. The extensive worldwide research that followed was crucial to our understanding of what cells and molecules regulate T cell activation and how this may be used to our benefit in the clinic.

Krishan Maggon 's curator insight, April 14, 2015 12:11 AM

Cancer Cell

 

Volume 27, Issue 4, p439–449, 13 April 2015

 

The Journey from Discoveries in Fundamental Immunology to Cancer ImmunotherapyJacques F.A.P. Miller, Michel Sadelain DOI: http://dx.doi.org/10.1016/j.ccell.2015.03.007